OncoMatch/Clinical Trials/NCT07892183
SPADE Clinical Trial.
Official title: Spade-Shaped Anastomosis After Laparoscopic or Robotic Proximal Gastrectomy Using Double Suture Anchoring Between the Posterior Wall of the Esophagus and the Anterior Wall of the Stomach (SPADE Operation): a Multicenter Prospective Clinical Trial.
Is NCT07892183 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for early gastric cancer.
Purpose: This multicenter, prospective, single-arm phase 2 clinical trial aims to evaluate the safety, feasibility, and clinical outcomes of the SPADE operation (Spade-Shaped Anastomosis) in patients undergoing laparoscopic or robotic proximal gastrectomy for early gastric cancer located in the upper stomach . Background: While proximal gastrectomy (removing only the upper part of the stomach) offers nutritional advantages over total gastrectomy, it often leads to significant postoperative reflux esophagitis * The SPADE technique was developed to prevent this by creating an artificial anti-reflux mechanism (angle of His and pseudo-fornix) using double suture anchoring between the esophagus and the stomach Study Plan: Participants: The study will enroll approximately 159 patients with tumors (size ≤ 4 cm) located in the upper third of the stomach who are eligible for gastric function-preserving surgery . Intervention: All participants will undergo laparoscopic or robotic proximal gastrectomy followed by the SPADE reconstruction method . Primary Objective: The primary goal is to determine the incidence of endoscopic reflux esophagitis at one year postoperatively . Secondary Objectives: Investigators will also monitor postoperative reflux symptoms, nutritional parameters (such as weight, hemoglobin, and vitamin B12 levels), surgical complications, quality of life, and 3-year survival rates . Hypothesis: The researchers hypothesize that the SPADE operation is a safe and effective surgical approach that can provide equivalent reflux prevention (a target rate of approximately 2.9%) compared to existing complex reconstruction methods, while maintaining the benefits of preserving gastric function
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage T1N0, T1N1, T2N0, T2N1, T3N0, T3N1
Grade: any differentiation (T1/T2), well or moderate differentiation (T3)
Preoperative clinical stage: T1N0, T1N1, T2N0, T2N1 (any differentiation); T3N0, T3N1 (well or moderate differentiation)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07892183 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage T1N0 or T1N1 or T2N0 or T2N1 or T3N0 or T3N1 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages